Incretin Therapies in Obesity-related HFpEF
Eligible age
40+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this will establish an important mechanism of clinical benefit and inform disease pathophysiology. To accomplish this, this study will perform a 15-month prospective cohort study in 50 patients with obesity and HFpEF who clinically qualify for treatment with tirzepatide. The investigators will serially measure plasma volume and body composition with quantitative magnetic resonance to determine changes over time with tirzepatide treatment.
Sponsor: Columbia University
You may qualify if…
- ✓ Diagnosis of heart failure (HF) per the ACC/AHA guidelines with NYHA class II-III symptoms
- ✓ Left ventricular ejection fraction \>= 45% within 6 months of recruitment
- ✓ At least one of the following: elevated N-terminal pro- B-type natriuretic peptide (NT-proBNP) \>=200 pg/ml (\>=600 pg/ml with concurrent atrial fibrillation), evidence of structural heart disease (left atrial (LA) enlargement with LA volume index \>29 mL/m2 or LA diameter \>=40 mm in males/\>38= mm in females), elevated filling pressures (resting wedge \>15 mmHg or exercise wedge \>25 mmHg, lateral E/e' ratio \>12 or septal E/e' \> 15)
- ✓ Body mass index (BMI) \>30 kg/m2
- ✓ Stable doses of HF medications within 4 weeks of screening with optimal volume control in the opinion of the investigator.
You may not qualify if…
- ✕ Acute decompensated HF within 4 weeks of screening
- ✕ Major cardiovascular event within 90 days of screening (myocardial infarction, stroke)
- ✕ Alternate cause of HFpEF such as cardiac amyloidosis, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease
- ✕ Estimated glomerular fibrilation rate (EGFR) \<15 ml/min/1.73m2 or dialysis dependence
- ✕ Poorly controlled diabetes (A1c \> 9.5%) OR any type 1 diabetes mellitis
- ✕ History of acute or chronic pancreatitis
- ✕ Personal or family history of multiple endocrine neoplasia (MEN) or medullary thyroid cancer
- ✕ Clinically significant gastric emptying abnormality
Where it's recruiting
New York
Source: ClinicalTrials.gov · NCT07554638 · last updated 2026-08-24